New research suggests that patients who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end conventional lifestyle regimens.
Findings released in a major health publication points out that while obese people often shed substantial amounts of their body weight while on the medication, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using such treatments need to be aware of the danger of rapid rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.
That rate of recovery implies a return to original mass within about a year and a half.
Comparing Therapies
The research, which looked at 37 of trials involving thousands of participants, compared the effects of GLP-1 agonists with conventional dieting.
Researchers emphasize that people who lose weight through dieting typically experience a less rapid weight regain—approximately 100 grams monthly—after stopping.
Explaining the Quick Regain
Doctors propose the way of the jabs accounts for the heightened regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication leads to appetite is unsuppressed, making excessive eating far more likely."
A Lifelong Condition?
Medical guidelines advise the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts say that, due to the likelihood of relapse, the therapy should be considered life-long.
This perspective is reinforced by pharmaceutical companies, who say that the results "emphasize the long-term character of obesity," similar to managing diseases like high blood pressure.
Patient Accounts
Users who have discontinued the jabs describe a sudden return of cravings.
"I experienced a trigger flipping and you're instantly ravenous," said an individual.
This difficulty is worsened if patients have not adopted permanent lifestyle or habit changes during therapy.
Significant Interest
Survey data suggest that millions of people in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Use is higher among females than males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians caution that while the jabs are powerful agents for weight loss, they are not a standalone cure and maintained weight loss hinges on combined lifestyle management.
